ECSP12011799A - Compuestos de espiropiperidina y uso farmacéutico de los mismos - Google Patents

Compuestos de espiropiperidina y uso farmacéutico de los mismos

Info

Publication number
ECSP12011799A
ECSP12011799A ECSP12011799A ECSP12011799A EC SP12011799 A ECSP12011799 A EC SP12011799A EC SP12011799 A ECSP12011799 A EC SP12011799A EC SP12011799 A ECSP12011799 A EC SP12011799A
Authority
EC
Ecuador
Prior art keywords
espiropiperidine
pharmaceutical use
same compounds
compounds
compound
Prior art date
Application number
Other languages
English (en)
Spanish (es)
Inventor
Chafiq Hamdouchi
Jayana Pankaj Lineswala
Pranab Maiti
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43719548&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP12011799(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP12011799A publication Critical patent/ECSP12011799A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ECSP12011799 2009-10-15 2012-04-13 Compuestos de espiropiperidina y uso farmacéutico de los mismos ECSP12011799A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25183909P 2009-10-15 2009-10-15
US30333410P 2010-02-11 2010-02-11
PCT/US2010/052126 WO2011046851A1 (en) 2009-10-15 2010-10-11 Spiropiperidine compounds and pharmaceutical use thereof for treating diabetes

Publications (1)

Publication Number Publication Date
ECSP12011799A true ECSP12011799A (es) 2012-07-31

Family

ID=43719548

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP12011799 ECSP12011799A (es) 2009-10-15 2012-04-13 Compuestos de espiropiperidina y uso farmacéutico de los mismos

Country Status (25)

Country Link
US (1) US8383642B2 (enExample)
EP (1) EP2488500A1 (enExample)
JP (1) JP2013508279A (enExample)
KR (1) KR20120051777A (enExample)
CN (1) CN102574807A (enExample)
AR (1) AR078522A1 (enExample)
AU (1) AU2010307094A1 (enExample)
BR (1) BR112012008889A2 (enExample)
CA (1) CA2777775A1 (enExample)
CL (1) CL2012000921A1 (enExample)
CO (1) CO6531458A2 (enExample)
CR (1) CR20120177A (enExample)
DO (1) DOP2012000105A (enExample)
EA (1) EA201270560A1 (enExample)
EC (1) ECSP12011799A (enExample)
IL (1) IL218344A0 (enExample)
MA (1) MA33662B1 (enExample)
MX (1) MX2012004420A (enExample)
NZ (1) NZ598972A (enExample)
PE (1) PE20121437A1 (enExample)
PH (1) PH12012500705A1 (enExample)
TN (1) TN2012000152A1 (enExample)
TW (1) TW201124415A (enExample)
WO (1) WO2011046851A1 (enExample)
ZA (1) ZA201202560B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20120834A1 (es) 2009-03-23 2012-07-25 Glenmark Pharmaceuticals Sa Derivados de furopirimidindiona como moduladores de trpa1
ES2456515T3 (es) 2009-03-23 2014-04-22 Glenmark Pharmaceuticals S.A. Derivados de pirimidindiona fusionados como moduladores de TRPA1
AR078948A1 (es) 2009-11-30 2011-12-14 Lilly Co Eli Compuestos de espiropiperidina, composicion farmaceutica que lo comprenden y su uso para preparar un medicamento util para tratar la diabetes
PH12012501456A1 (en) 2009-12-25 2012-10-29 Mochida Pharm Co Ltd Novel 3-hydroxy -5- arylisothiazole derivative
AU2011313191A1 (en) 2010-10-08 2013-05-02 Mochida Pharmaceutical Co., Ltd. Cyclic amide derivative
EP2683251B1 (en) 2011-03-11 2021-08-25 Intercontinental Great Brands LLC Method of forming multilayer confectionery
AR085990A1 (es) 2011-04-27 2013-11-13 Mochida Pharm Co Ltd Derivados de 1-oxido de 3-hidroxiisotiazol utiles en el tratamiento de la diabetes y composiciones farmaceuticas que los contienen
JPWO2012147516A1 (ja) 2011-04-28 2014-07-28 持田製薬株式会社 環状アミド誘導体
AR087451A1 (es) 2011-08-17 2014-03-26 Lilly Co Eli Derivado de 1,2,3,4-tetrahidroquinolina util para tratamiento de diabetes
WO2013139341A1 (en) * 2012-03-20 2013-09-26 Syddansk Universitet Gpr120 receptor modulators
WO2013185766A1 (en) * 2012-06-15 2013-12-19 Syddansk Universitet Gpr120 receptor modulators
UY35143A (es) 2012-11-16 2014-05-30 Bristol Myers Squibb Co Derivados de dihidropirazol como moduladores del receptor acoplado a la proteína gpr40 g
KR101569522B1 (ko) * 2013-04-18 2015-11-17 현대약품 주식회사 신규한 3-(4-(벤질옥시)페닐)헥스-4-이노익 산 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 대사성 질환의 예방 또는 치료용 약학적 조성물
CN105722841A (zh) * 2013-11-14 2016-06-29 卡迪拉保健有限公司 新型杂环化合物
US20150351889A1 (en) 2014-06-05 2015-12-10 Vivex Biomedical Inc. Dynamic Biometric Mesh
EP3207928B1 (en) * 2014-10-17 2021-03-10 Hyundai Pharm Co., Ltd. Composite preparation, containing novel 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative and another active ingredient, for preventing or treating metabolic diseases
BR102018007822A2 (pt) 2017-04-20 2018-11-06 Gilead Sciences, Inc. composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
CN109666027A (zh) * 2017-10-17 2019-04-23 中国科学院上海药物研究所 一类酰胺结构的gpr40激动剂化合物及其用途
DK3737470T5 (da) 2018-01-08 2024-05-27 Celon Pharma Sa 3-phenyl-4-hexynsyrederivater som gpr40-agonister
WO2019160882A1 (en) 2018-02-13 2019-08-22 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
KR102591947B1 (ko) 2018-04-19 2023-10-25 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
PE20210642A1 (es) 2018-07-13 2021-03-23 Gilead Sciences Inc Inhibidores de pd-1/pd-l1
US11236085B2 (en) 2018-10-24 2022-02-01 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
JP2022552655A (ja) 2019-10-07 2022-12-19 キャリーオペ,インク. Gpr119アゴニスト
MX2022010548A (es) 2020-02-28 2022-09-23 Kallyope Inc Agonistas de gpr40.
MX2022014505A (es) 2020-05-19 2022-12-13 Kallyope Inc Activadores de la ampk.
CA3183575A1 (en) 2020-06-26 2021-12-30 Iyassu Sebhat Ampk activators

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2033644A1 (en) 2001-04-18 2009-03-11 Euro-Celtique S.A. Spiroindene and spiroindane compounds
CA2520114A1 (en) * 2003-04-04 2004-10-21 Merck & Co., Inc. Acylated spiropiperidine derivatives as melanocortin-4 receptor agonists
US7504506B2 (en) 2003-11-04 2009-03-17 Elixir Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
WO2005051890A1 (en) 2003-11-19 2005-06-09 Smithkline Beecham Corporation Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to gpr40
EP1737809B1 (en) 2004-02-27 2013-09-18 Amgen, Inc Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
JP4859665B2 (ja) 2004-03-30 2012-01-25 武田薬品工業株式会社 アルコキシフェニルプロパン酸誘導体
US7582803B2 (en) 2005-09-14 2009-09-01 Amgen Inc. Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders
EP2061760A1 (en) 2006-09-07 2009-05-27 Amgen, Inc Benzo-fused compounds for use in treating metabolic disorders
TWI421070B (zh) 2007-10-26 2014-01-01 Japan Tobacco Inc 螺化合物及其醫藥用途
EP2224803B1 (en) 2007-11-21 2014-04-02 Janssen Pharmaceutica N.V. Spiropiperidines for use as tryptase inhibitors
AR078948A1 (es) 2009-11-30 2011-12-14 Lilly Co Eli Compuestos de espiropiperidina, composicion farmaceutica que lo comprenden y su uso para preparar un medicamento util para tratar la diabetes

Also Published As

Publication number Publication date
CR20120177A (es) 2012-06-06
AR078522A1 (es) 2011-11-16
PE20121437A1 (es) 2012-10-26
CL2012000921A1 (es) 2012-09-14
CA2777775A1 (en) 2011-04-21
NZ598972A (en) 2013-06-28
EA201270560A1 (ru) 2012-09-28
DOP2012000105A (es) 2013-01-31
JP2013508279A (ja) 2013-03-07
EP2488500A1 (en) 2012-08-22
CO6531458A2 (es) 2012-09-28
PH12012500705A1 (en) 2012-10-29
MX2012004420A (es) 2012-05-08
MA33662B1 (fr) 2012-10-01
US20110092531A1 (en) 2011-04-21
WO2011046851A1 (en) 2011-04-21
TW201124415A (en) 2011-07-16
AU2010307094A1 (en) 2012-04-19
KR20120051777A (ko) 2012-05-22
IL218344A0 (en) 2012-04-30
CN102574807A (zh) 2012-07-11
BR112012008889A2 (pt) 2019-09-24
US8383642B2 (en) 2013-02-26
TN2012000152A1 (en) 2013-12-12
ZA201202560B (en) 2013-09-25

Similar Documents

Publication Publication Date Title
CO6531458A2 (es) Nuevos compuestos de espiropiperidina
CR20120296A (es) Nuevos compuestos de espiropiperidina
UY32153A (es) Inhibidores de piridomidinona de pi13ka(alfa) y mtor
CO6620055A2 (es) Ciertas amino-pirimidinas, composiciones de las mismas y métodos para el uso de los mismos
BR112012026767A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, método para tratar ou previnir distúrbios, e, uso de um composto ou sal
UY32062A (es) Inhibidores de beta-secretasa
CL2013002417A1 (es) Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas.
CO6630154A2 (es) Ciertas amino-piridazinas, composiciones de las mismas y métodos de uso de los mimos
ECSP11011258A (es) Pirimidinas fusionadas
UY32490A (es) Inhibidores de beta-secretasa
MX2016006336A (es) Compuestos pirazolopirimidina.
BRPI1015983A2 (pt) composto, uso do composto, método para tratar um paciente, e, composição farmacêutica.
GT201400111A (es) Triazolopiridinas sustituidas
CL2015002698A1 (es) Nuevos compuestos y composiciones para la inhibicion de fasn
EA201001205A1 (ru) Соединения, содержащие циклобутоксигруппу
AR077629A1 (es) Mimetico de smac
CL2011000558A1 (es) Formas cristalinas de un compuesto derivado de 2-tiazolil-4-quinolinil-oxi; sal de sodio del compuesto, composicion farmaceutica que comprende la sal de sodio, util para tratar una infeccion por el virus de la hepatitis c.
CL2014001154A1 (es) Compuestos derivados antibioticos de 2-oxo-oxazolidin-3,5-diilo de formula i; composicion farmaceutica; uso para la prevencion o tratamiento de una infeccion bacteriana.
AR085616A1 (es) Composicion farmaceutica inhalable que comprende glicopirrolato, uso
EA201200616A1 (ru) Производные 2-оксо-1-пирролидинилимидазотиадиазола
CR20160016A (es) Pirazolpiridinas sustituidas
ECSP10010168A (es) Benzotiazolas como moduladores del receptor de ghrelina
UY32674A (es) Derivados heterociclicos de la urea y sus metodos de empleo
EA201001855A1 (ru) Соединения, содержащие циклобутоксигруппу
AR091888A1 (es) Compuestos de urea y su uso como inhibidores de enzimas